v3.26.1
Intangible Assets (Details)
12 Months Ended
Jun. 25, 2024
USD ($)
Jun. 19, 2024
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 25, 2024
TWD ($)
Intangible Assets [Line Items]              
Licensed period 10 years            
Royalties of the sales of products   10.00%          
Global patent including VAT   $ 5,000,000          
Value added tax   $ 4,761,905          
Development costs     $ 1,550,000        
Equity interest 45.30%           45.30%
Pay of royalty     7.00%        
Royalty expenses     $ 2,273      
Amortization expense     193,314 $ 94,536    
Three D Global Patent [Member]              
Intangible Assets [Line Items]              
Licensed period   20 years          
Useful life   15 years          
Global patent including VAT           $ 1,000,000  
Value added tax           $ 952,381  
Research and development expense     $ 1,970,000        
EG BioMed Patent [Member]              
Intangible Assets [Line Items]              
Useful life 15 years           15 years
Finite-Lived Patents, Gross $ 1,830,000           $ 60,000,000
Minimum [Member]              
Intangible Assets [Line Items]              
Royalties of the sales of products     7.00%        
Maximum [Member]              
Intangible Assets [Line Items]              
Royalties of the sales of products     10.00%        
3D Global Biotech Inc. [Member] | Common Share [Member]              
Intangible Assets [Line Items]              
Owned on the date of transaction   14.97%          
EG BioMed Co., Ltd [Member] | Director [Member]              
Intangible Assets [Line Items]              
Owned on the date of transaction 46.16%           46.16%